Regimen Reference Order – BRST – trastuzumab deruxtecan (ENHERTU)

ARIA: BRST – [ENHERTU]

Planned Course: **Every 3 weeks until disease progression or unacceptable toxicity**
Indication for Use: **Breast Cancer Metastatic or Locally Advanced, HER2-positive**

CVAD: At Provider's Discretion

Proceed with treatment if:
ANC equal to or greater than 1.5 x 10^9/L AND Platelets equal to or greater than 50 x 10^9/L
- **Contact Physician if parameters not met**

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – BRST – trastuzumab deruxtecan (ENHERTU)

Establish primary solution 500 mL of: D5W

Drug	Dose	CCMB Administration Guideline
dexamethasone	12 mg	Orally 30 minutes pre-chemotherapy
ondansetron	16 mg	Orally 30 minutes pre-chemotherapy
trastuzumab deruxtecan (ENHERTU®)	5.4 mg/kg	IV in D5W 100 mL • Dose 1 to be infused over 90 minutes • Dose 2 and subsequent to be infused over 30 minutes (if first dose well tolerated) *Use 0.2 or 0.22 micron filter* **Alert: Ensure that* trastuzumab deruxtecan (ENHERTU®) *is dispensed and administered*

In the event of an infusion-related hypersensitivity reaction, refer to the **'Hypersensitivity Reaction Standing Order'**

REQUIRED MONITORING

All Cycles
- CBC, serum creatinine, urea, electrolytes, liver enzymes and total bilirubin as per Physician Orders

Cardiac Monitoring
- Left Ventricular Ejection Fraction (LVEF) monitoring is recommended at baseline and every 4 cycles for the first 2 years then every 4 to 8 cycles thereafter

Cycle 1 Only

- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O_2 saturation) at baseline and as clinically indicated
- Observe patient for 90 minutes after administration
- Full vital signs prior to discharge

Cycle 2 and Onwards

- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O_2 saturation) at baseline and as clinically indicated
- Observe patient for 30 minutes after administration of Cycles 2 and 3 only
- Full vital signs prior to discharge

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
dexamethasone	8 mg	Orally once daily on Days 2 and 3
metoclopramide	10 – 20 mg	Orally every 4 hours as needed for nausea and vomiting

DISCHARGE INSTRUCTIONS

- Patients should be instructed to contact their cancer team immediately if symptoms of hypersensitivity reactions occur after discharge
- Patient should report any new or worsening respiratory symptom such as dyspnea, cough or fever
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

ADDITIONAL INFORMATION

- trastuzumab deruxtecan (ENHERTU®) can cause interstitial lung disease and pneumonitis
- There is a risk of medication errors between trastuzumab deruxtecan (ENHERTU®), T-DM1 (KADCYLA®) and trastuzumab. In order to minimize the risk, check the regimen ordered, the vial labels, and the prescription label to ensure that the drug being prepared and administered is trastuzumab deruxtecan (ENHERTU®)